Skip to main content
SpringerLink
Log in

Triglyceride-Rich Lipoproteins

  • Chapter
Atlas of Atherosclerosis

  • 123 Accesses

Abstract

Elevated plasma triglycerides (TG) are an indicator of increased risk of arteriosclerotic vascular disease. However, the relationship between atherogenesis and increased levels of specific TG-carrying lipoproteins is complex and convoluted. Several primary and secondary disorders cause plasma triglyceride elevations. An increase in the risk of arteriosclerotic disease is observed in some of these disorders. Risk appears more strongly associated with concomitant alterations in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) metabolism and with the accumulation of partially digested TG-rich lipoproteins, commonly referred to as “remnant” lipoproteins. In addition, the association of hypertriglyceridemia with other risk factors, such as diabetes mellitus and high blood pressure, causes linkage to atherosclerosis in epidemiologic studies to be less clear-cut.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lipid Research Clinics Program Epidemiology Committee: Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1979, 60: 427–438.

    Article  Google Scholar 

  2. Castelli W, Garrison RJ, Wilson PWF, et al.: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986, 256:2835–2838.

    Google Scholar 

  3. The International Committee for the Evaluation of Hypertriglyceridemia as a Vascular Risk Factor (Chairs: Assmann G, Gotto AM Jr, Paoletti R): The hypertriglyceridemias risk and management. Am J Cardiol 1991, 68: 1A - 42A.

    Article  Google Scholar 

  4. Bainton D, Miller NE, Bolton CH, et al.: Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischemic heart disease in British men. Br Heart J 1992, 68:60–66.

    Google Scholar 

  5. Assmann G, Schulte H: Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol 1992, 70: 10H - 13H.

    Article  PubMed  CAS  Google Scholar 

  6. Eisenberg S: Lipoprotein abnormalities in hypertriglyceridemia: significance in atherosclerosis. Am Heart J 1987, 113: 55–61.

    Article  Google Scholar 

  7. Austin MA: Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991, 11: 2–14.

    Article  PubMed  CAS  Google Scholar 

  8. Davis CE, Gordon D, LaRosa J, et al.: Correlations of plasma high-density lipoprotein cholesterol levels with other plasma lipid and lipoprotein concentrations. The Lipid Research Clinics Program Prevalence Study. Circulation 1980, 62(suppl IV):IV-24-IV-30.

    Google Scholar 

  9. Austin MA, Brunzell JD, Fitch WL, et al.: Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 1990, 10:520–530.

    Google Scholar 

  10. Reaven GM: Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med 1991, 90: 7S - 12S.

    Article  PubMed  CAS  Google Scholar 

  11. Fontbonne A, Eschwege E: Insulin-resistance, hypertriglyceridemia and cardiovascular risk: the Paris Prospective Study. Diabetes Metab 1991, 17: 93–95.

    CAS  Google Scholar 

  12. Kaplan NM: The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989, 149: 1514–1520.

    Article  PubMed  CAS  Google Scholar 

  13. Austin MA: Triglycerides, small dense LDL and coronary disease. Atherosclerosis 1994, 109: 259.

    Article  Google Scholar 

  14. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease: Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993, 269: 505–510.

    Google Scholar 

  15. Ameis D, Kobayashi J, Davis RC, et al.: Familial chylomicronemia (type I hyperlipoproteinemia) due to a single missense mutation in the lipoprotein lipase gene. J Clin Invest 1991, 87:1165–1170.

    Google Scholar 

  16. Ma Y, Henderson HE, Murthy VA, et al.: A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomicronemia in French Canadians. N Engl J Med 1991, 324:1761–1766.

    Google Scholar 

  17. Brewer HB Jr, Rader DJ, Hoeg JM, et al.: Recent advances in lipoprotein metabolism and the genetic dyslipoproteinemias. Adv Exp Med Biol 1991, 285:237–244.

    Google Scholar 

  18. Sniderman A, Brown BG, Stewart BF, et al.: From familial combined hyperlipidemia to hyperapoB: unravelling the overproduction of hepatic apolipoprotein B. Curr Opin Lipid 1992, 3:137–142.

    Google Scholar 

  19. Mahley RW, Weisgraber KH, Innerarity TL, et al.: Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. JAMA 1991, 265:78–83.

    Google Scholar 

  20. Durrington PN: Secondary hyperlipidemia. Br Med Bull 1990, 46: 1005–1024.

    PubMed  CAS  Google Scholar 

  21. Fujioka S, Matsuzawa Y, Tokunaga K, et al.: Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987, 36:54–59.

    Google Scholar 

  22. Brown WV: Lipoprotein disorders in diabetes mellitus. Med Clin North Am 1994, 78: 143–161.

    CAS  Google Scholar 

  23. Appel G: Lipid abnormalities in renal disease [clinical conference]. Kidney Int 1991, 39: 169–183.

    Article  PubMed  CAS  Google Scholar 

  24. Palella TD, Fox IH: Hyperuricemia and gout. In The Metabolic Basis of Inherited Disorders, ed 6. Edited by Scriver CR, Beaudet AL, Sly WS, et al. New York: McGraw Hill Inc; 1989: 965–1006.

    Google Scholar 

  25. Hers HG, van Hoof F, de Barsy T: Glycogen storage diseases. In Metabolic Basis of Inherited Disorders, ed 6. Edited by Scriver CR, Beaudet AL, Sly WS, et al. New York: McGraw Hill; 1989: 425–452.

    Google Scholar 

  26. Pathogenesis of alcohol-induced hypertriglyceridemia. Nutr Rev 1987, 45: 215–216.

    Google Scholar 

  27. Glueck CJ, Scheel D, Fishback J, et al.: Estrogen-induced pancreatitis in patients with previously covert familial type V hyperlipoproteinemia. Metabolism 1972, 21:657–666.

    Google Scholar 

  28. Davidoff F, Tishler S, Rosoff C: Marked hyperlipidemia and pancreatitis associated with oral contraceptive therapy. N Engl J Med 1973, 289: 552–555.

    Article  PubMed  CAS  Google Scholar 

  29. Marsden J: Hyperlipidemia due to isotretinoin and etretinate: possible mechanisms and consequences. Br J Dermatol 1986, 114: 401–407.

    Article  PubMed  CAS  Google Scholar 

  30. Ames RP: The effects of antihypertensive drugs on serum lipids and lipoproteins. I. Diuretics. Drugs 1986, 32: 260–278.

    Article  PubMed  CAS  Google Scholar 

  31. Hunninghake DB: The effects of cardioselective vasodilating n-blockers on lipids. Am Heart J 1991, 121: 1029–1032.

    Article  PubMed  CAS  Google Scholar 

  32. Ginsberg HN: Lipoprotein physiology and its relationship to atherogenesis. Endocrinol Metab Clin North Am 1990, 19: 211–228.

    PubMed  CAS  Google Scholar 

  33. Havel RJ: Role of triglyceride-rich lipoproteins in progression of atherosclerosis [comment]. Circulation 1990, 81: 694–696.

    Article  PubMed  CAS  Google Scholar 

  34. Austin MA, Breslow JL, Hennekens CH, et al.: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917–1921.

    Google Scholar 

  35. Sniderman A, Shapiro S, Marpole D, et al.: Association of coronary atherosclerosis with hyperapobetalipoproteinemia: increased protein but normal cholesterol levels in human plasma low density (ß lipoprotein). Proc Natl Acad Sci USA 1980, 77:605–608.

    Google Scholar 

  36. Hamsten A: Hypertriglyceridemia, triglyceride-rich lipoproteins and coronary heart disease. Clin Endocrinol Metab 1990, 4: 895–922.

    CAS  Google Scholar 

  37. Brewer HB Jr, Gregg RE, Hoeg JM, et al.: Apolipoproteins and lipoproteins in human plasma: an overview. Clin Chem 1988, 34:B4–B8.

    Google Scholar 

  38. Beisiegel U, Weber W, Ihrke G, et al.: The LDL receptor related protein, LRP, is an apolipoprotein E binding protein. Nature 1989, 341:162–164.

    Google Scholar 

  39. Rubinstein A, Gibson JC, Paterniti JR: The effect of heparin induced lipolysis on the distribution of apolipoprotein E among lipoprotein subclasses. J Clin Invest 1985, 75: 710–721.

    Article  CAS  Google Scholar 

  40. Goldberg IJ, Le N-A, Paterniti JR, et al.: Effect of acute inhibition of hepatic triglyceride lipase on very low density lipoprotein metabolism in the cynomolgus monkey. J Clin Invest 1982, 70:1184–1192.

    Google Scholar 

  41. Cortner JA, Le N-A, Coates PM, et al.: Determinants of fasting plasma triglyceride levels: metabolism of hepatic and intestinal lipoproteins. Eur J Clin Invest 1991, 22:158–165.

    Google Scholar 

  42. Le N-A, Innis W, Umeakunne K, et al.: Accelerated clearance of postprandial lipoproteins with HMG CoA reductase inhibitor. AFCR National Meeting May 5–8,1995. J Invest Med 1995, 43:301A.

    Google Scholar 

  43. de Silva H, Lauer SJ, Wang J, et al.: Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994, 269:2324–2335.

    Google Scholar 

  44. Lagrost L, Gandjini H, Athias A, et al.: Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb 1992, 13:815–825.

    Google Scholar 

  45. Kuusi T, Saarinen P, Nikkila EA: Evidence for the role of hepatic lipase in the metabolism of plasma HDL2 in man. Atherosclerosis 1980, 36: 589–593.

    Article  PubMed  CAS  Google Scholar 

  46. Hongmei L, Myron I, Cybulsky MA, et al.: An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993,13:197–204.

    Google Scholar 

  47. de Gruijter M, Hoogerbrugge N, van Rijn MA, et al.: Patients with combined hypercholesterolemia-hypertriglyceridemia shown an increased monocyte-endothelial cell adhesion in vitro: triglyceride level as a major determinant. Metabolism 1991, 40:1119–1121.

    Google Scholar 

  48. Chung BH, Segrest JP: Cytotoxicity of remnants of triglyceride-rich lipoproteins: an atherogenic insult? Adv Exp Med Biol 1991, 285: 341–351.

    Article  PubMed  CAS  Google Scholar 

  49. Wang-Iverson P, Gibson JC, Brown WV: Plasma apolipoprotein E secretion by human monocyte-derived macrophages. Biochim Biophys Acta 1985, 834: 256–262.

    Article  CAS  Google Scholar 

  50. Rosenfeld ME, Khoo JC, Miller E, et al.: Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. J Clin Invest 1991, 87:90–99.

    Google Scholar 

  51. David JB, Bowyer DE: Macrophages modify ß-VLDL by proteolysis and enhance subsequent lipid accumulation in arterial smooth muscle cells. Atherosclerosis 1989, 77: 203–208.

    Article  Google Scholar 

  52. Mitropoulos KA, Miller GJ, Reeves BE, et al.: Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989, 76:203–208.

    Google Scholar 

  53. Miller GJ, Martin JC, Mitropoulos KA, et al.: Factor VII and dietary fat intake. Adv Exp Med Biol 1990, 281:145–149.

    Google Scholar 

  54. Hosoai H, Nakamura H: Triglyceride as a risk factor for atherothrombotic disease through increased plasminogen activator inhibitor. In Current Advances in Triglycerides and Atherosclerosis. Edited by Yamamoto A, Nakamura H, Tsuguhiko N. Osaka: Churchill Livingstone; 1994: 115–118.

    Google Scholar 

  55. Mehta J, Mehta P, Lawson D, et al.: Plasma tissue activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987, 9:263–267.

    Google Scholar 

  56. Mussoni L, Mannucci L, Sirtori M, et al.: Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992, 12:19–25.

    Google Scholar 

  57. Hiraga T, Murase T, Tsukada T: Blood coagulation and fibrinolysis in patients with hypertriglyceridemia. In Current Advances in Triglycerides and Atherosclerosis. Edited by Yamamoto A, Nakamura H, Tsuguhiko N. Osaka: Churchill Livingstone; 1994: 109–114.

    Google Scholar 

  58. Zannis VI, Breslow JL: Characterization of a unique human apolipoprotein E variant associated with type III hyperlipoproteinemia. J Biol Chem 1980, 255: 1759.

    CAS  Google Scholar 

  59. Rall SC Jr, Weisgraber KH, Innerarity TL, et al.: Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci USA 1982, 79:4696.

    Google Scholar 

  60. Fredrickson DS, Morganroth J, Levy RI: Type III hyperlipoproteinemia: an analysis of two contemporary definitions. Ann Intern Med 1975, 82: 150.

    Article  PubMed  CAS  Google Scholar 

  61. Goldstein JL, Schrott HG, Hazzard WR, et al.: Hyperlipidemia in coronary artery disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973, 2:1544–1568.

    Google Scholar 

  62. Cortner JA, Coates PM, Bennett MJ, et al.: Familial combined hyperlipidaemia: use of stable isotopes to demonstrate overproduction of very low-density lipoprotein apolipoprotein B by the liver. J Inherit Metab Dis 1991,14:915–922.

    Google Scholar 

  63. Janus CK, Nicoll AM, Turner PR, et al.: Kinetic basis of the primary hyperlipidemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest 1980,10:161–172.

    Google Scholar 

  64. Kissebah AH, Alfarsi S, Evans DJ: Low density lipoprotein metabolism in familial combined hyperlipidemia. Mechanisms of the multiple lipoprotein phenotypic expression. Arteriosclerosis 1984, 4: 614–624.

    Article  PubMed  CAS  Google Scholar 

  65. Kesaniemi YA, Vega GL, Grundy SM: Kinetics of apolipoprotein B in normal and hyperlipidemic man: review of current data. In Lipoprotein Kinetics and Modeling. Edited by Berman M, Grundy SM, Howard BV. New York: Academic Press; 1982: 181–205.

    Chapter  Google Scholar 

  66. Chait A, Robertson HT, Brunzell JD: Chylomicronemia syndrome in diabetes mellitus. Diabetes Care 1981, 4: 343–348.

    Article  PubMed  CAS  Google Scholar 

  67. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14: 173–194.

    Article  PubMed  CAS  Google Scholar 

  68. Goldschmid MG, Barrett-Connor E, Edelstein SL, et al.: Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. Circulation 1994, 89:991–997.

    Google Scholar 

  69. Bonora E, Zenere M, Branzi P, et al.: Influences of body fat and its regional localization on risk factors for atherosclerosis in young men. Am J Epidemiol 1992,135:1272–1278.

    Google Scholar 

  70. Leenan R, van der Kooy K, Seidell JC, et al.: Visceral fat accumulation measured by magnetic resonance imaging in relation to serum lipids in obese men and women. Atherosclerosis 1992, 94:171–181.

    Google Scholar 

  71. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223: 405–418.

    Article  PubMed  CAS  Google Scholar 

  72. Frick MH, Elo H, Haapa K, et al.: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987, 317:1237–1245.

    Google Scholar 

  73. Manninen V, Elo O, Frick MH, et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988, 260:641–651.

    Google Scholar 

  74. Manninen V, Huttunen JK, Heinonen OP, et al.: Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol 1989, 63:42H–47H.

    Google Scholar 

  75. Rubins HB, Robins SJ, Collins D, >et alfor the VA-HIT Study Group: N Engl J Med 1999, 341:410–418.

    Google Scholar 

  76. Karathanasis SK, Norum RA, Zannis VI, JL Breslow VI: Linkage of human apolipoproteins A-I and C-III genes. Nature 1983, 304: 371–373.

    Article  PubMed  CAS  Google Scholar 

  77. Dallinga-Thie GM, Bu X-D, van Linde-Sibenius Trip M, et al.: Apolipoprotein A-I,/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-c and apoB and C-III. J Lipid Res 1996, 37:136–147.

    Google Scholar 

  78. Dallinga-Thie GM, van Linde-Sibenius Trip M, Rotter JI, et al.: Complex genetic contribution of the apoAI-CIII-AIV gene cluster to familial combined hyperlipidemia: identification of different susceptibility haplotypes. J Clin Invest 1997, 99:953–961.

    Google Scholar 

  79. Xu C-F, Talmud P, Schuster H, et al. Association between genetic variation at the apo AI-CIII-AIV gene cluster and familial combined hyperlipidemia. Clin Genet 1994, 46: 385–397.

    Article  PubMed  CAS  Google Scholar 

  80. Chen M, Breslow JL, Li W, Leff T:Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 1994, 35: 1918–1924.

    PubMed  CAS  Google Scholar 

  81. Gruber PJ, Torres-Rosado A, Wolak ML, Leff T: ApoC-III gene transcription is regulated by a cytokine-inducible NFKB element. Nucleic Acid Res 1994, 22: 2417–2422.

    Article  PubMed  CAS  Google Scholar 

  82. Reue K, Leff T, Breslow JL: Human apoC-III gene expression is regulated by positive and negative cis-acting elements and tissue-specific protein factors. J Biol Chem 1988, 263: 6857–6864.

    PubMed  CAS  Google Scholar 

  83. Ladias JAA, Hadzopoulou-Cladaras M, Kardassis D, et al.: Transcriptional regulation of human apolipoprotein genes apoB, apoC-III and apoA-II by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2 and EAR-3. J Biol Chem 1992, 267:15849–15860.

    Google Scholar 

  84. Hertz R, Bishara-Shieban J, Bar-Tana J: Mode of action of peroxisome proliferators as hypolipidemic drugs: suppression of apoCIII. J Biol Chem 1995, 270: 13470–13475.

    Article  PubMed  CAS  Google Scholar 

  85. Schonfeld G, George PK, Miller J, et al.: Apolipoprotein C-II and C- III levels in hyperlipoproteinemia. Metabolism 1979, 28:1001–1010.

    Google Scholar 

  86. Bukberg P, Le N-A, Gibson JC, et al.: Direct measurement of apoCIII specific activity in 125I-labeled VLDL by immunoaffinity chromatography. J Lipid Res 1983, 24:1251–1260.

    Google Scholar 

  87. Le N-A, Gibson JC, Ginsberg HN: Independent regulation of plasma apo C-II and C-III concentrations in very low density and high density lipoproteins: Implications for the regulation of the catabolism of these lipoproteins. J Lipid Res 1988, 29: 669–677.

    PubMed  CAS  Google Scholar 

  88. Havel RJ, Shore VG, Shore B, Bier DM: Role of specific glycopeptides of human serum lipoproteins in the activation of LPL. Circ Res 1970, 27: 375–381.

    Article  Google Scholar 

  89. Brown WV, Baginsky ML: Inhibition of lipoprotein lipase by an apoprotein of human VLDL. Biochem Biophys Res Commun 1972, 46: 375–381.

    Article  PubMed  CAS  Google Scholar 

  90. Ginsberg HN, Le N-A, Goldberg IJ, et al.: Apolipoprotein B metabolism in subjects with deficiency of apoC-III and A-I: Evidence that apoC-III inhibits catabolism of TG-rich lipoproteins by LPL in vivo. J Clin Invest 1986, 78:1287–1295.

    Google Scholar 

  91. Ito Y, Azrolan N, O’Connell A, et al.: Hypertriglyceridemia as a result of human apoC-III expression in transgenic mouse. Science 1990, 249:790–793.

    Google Scholar 

  92. Ebara T, Ramakrishnan R, Steiner G, Shachter NS: Chylomicronemia due to apoC-III overexpression in apoE-null mice: ApoC-III induced hypertriglyceridemia is not mediated by effects on apoE. J Clin Invest 1997, 99: 2672–2681.

    Article  PubMed  CAS  Google Scholar 

  93. Maeda N, Li H, Lee D, et al.: Targeted disruption of the apoC-II gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994, 269:23610–23616.

    Google Scholar 

  94. Staels B, Vu-Dac N, Kosykh VA, et al.: Fibrates downregulate apoC-III expression independent of induction of peroxisomal acyl CoA oxidase: A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995, 95:705–712.

    Google Scholar 

  95. Shelburne F, Hanks J, Myers W, Quarfordt S: Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest 1980, 65: 652–658.

    Article  PubMed  CAS  Google Scholar 

  96. Windler E, Havel RJ: Inhibitory effect of C apolipoproteins from rats and humans on the uptake of TG-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 1985, 26: 556–565.

    PubMed  CAS  Google Scholar 

  97. Kowal RC, Herz J, Weisgraber KH, et al.: Opposing effect of apoE and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 1990, 265:10771–10779.

    Google Scholar 

  98. Rensen PCN, Herijgers N, Netscher MH, et al.: Particle size determines the specificity of apoE-containing TG-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res 1997, 38:1070–1084.

    Google Scholar 

  99. Breyer ED, Le N-A, Li X, et al.:ApoC-III displacement of apoE from VLDL: effect of particle size. J Lipid Res 1999, in press.

    Google Scholar 

  100. Hazzard WR, Bierman EL: Delayed clearance of chylomicron remnants following vitamin A-containing oral fat loads in boradb-disease (type III hyperlipoproteinemia) Metabolism 1976, 25: 777–801.

    Article  PubMed  CAS  Google Scholar 

  101. Bergeron N, Havel RJ: Prolonged postprandial responses of lipids and apolipoproteins in TG-rich lipoproteins in individuals expressing an €4 allele. J Clin Invest 1996, 7: 65–72.

    Article  Google Scholar 

  102. Dallongeville J, Lussier-Cacan S, Davignon J: (1992) Modulation of plasma TG levels by apoE phenotype: a meta-analysis. J Lipid Res 1992, 33: 447–454.

    Google Scholar 

  103. Lenzen HJ, Assman G, Buchwalsky R, Schulte H: Association of apoE polymorphism, LDL, and CAD. Clin Chem 1986, 32: 778–781.

    PubMed  CAS  Google Scholar 

  104. Kuusi T, Nieminen MS, Ehnholm C, et al.: ApoE polymorphism and coronary artery disease: increased prevalence of E4 in angiographically verified coronary patients. Arteriosclerosis 1989, 9: 237–241.

    Google Scholar 

  105. Hixson JE for the PDAY Research Group: ApoE polymorphism affect atherosclerosis in young males. Arterioscl Thromb1991, 11: 1237–1244.

    Google Scholar 

  106. Van Bockxmeer FM, Mamotte CD: Apolipoprotein e4 homozygosity in young men with coronary artery disease. Lancet 1992, 340: 879–880.

    Article  PubMed  Google Scholar 

  107. Wilson PWF, Myers RH, Larson MG, et al.: ApoE alleles, dyslipidemia, and coronary heart disease: The Framingham Offspring Study. JAMA 1994, 272:1666–1671.

    Google Scholar 

  108. Levy RI, Brensike JF, Epstein SE, et al.: The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984, 69:325–337.

    Google Scholar 

  109. Phillips NR, Waters D Havel RJ: Plasma lipoproteins and progression of coronary artery disease of coronary artery disease evaluated by angiography and clinical events. Circulation 1993, 88: 2762–2770.

    Article  PubMed  CAS  Google Scholar 

  110. Groot PHE, van Stiphout WAHJ, Krauss XH, et al.: Postprandial lipoprotein metabolism in normolipidemic man with and without coronary artery disease. Arterioscler Thromb 1991, 11: 653–662.

    Google Scholar 

  111. Sharrett AR, Chambless LE, Heiss G, et al.: Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid atherosclerosis in middle-aged men and women: the ARIC Study. Arterioscler Thromb Vasc Biol 1995, 15: 2122–2129.

    Google Scholar 

  112. Watts GF, Lewis B, Brunt JNH, et al.: Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine in the St. Thomas Atherosclerosis Regression Study (STARS). Lancet 1992, 339:563–569.

    Google Scholar 

  113. Blankenhorn DH, Alaupovic P, Wickham E et al.: Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: Lipids and nonlipid factors. Circulation 1990, 81:470–76.

    Google Scholar 

  114. Hodis HN, Mack WJ, Azen SP, et al.: Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild-, moderate, and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994, 90:42–49.

    Google Scholar 

  115. Manninen V, Elo MO, Frick MH, et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988, 260: 641–651.

    Google Scholar 

  116. Ericsson C-G: Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. Eur Heart J 1998, 19 (Suppl H): H37 — H41.

    PubMed  Google Scholar 

  117. Austin MA: Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 1999, 83: 13F - 16F.

    Article  PubMed  CAS  Google Scholar 

  118. Criqui MH, Heiss G, Cohn R, et al.: Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993, 328:1220–1225.

    Google Scholar 

  119. Castelli WP: The triglyceride issue: a view from Framingham. Am Heart J 1986, 112: 432–437.

    Article  PubMed  CAS  Google Scholar 

  120. Miller M: Is hypertriglyceridemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart J 1998, 19: H18 — H22.

    PubMed  Google Scholar 

Download references

Authors
  1. Ngoc-Anh Le
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Virgil Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Boston University School of Medicine, Boston, Massachusetts, USA

    Peter W. F. Wilson MD (Professor of Medicine, Director of Laboratories) (Professor of Medicine, Director of Laboratories)

  2. Framingham Heart Study, Framingham, Massachusetts, USA

    Peter W. F. Wilson MD (Professor of Medicine, Director of Laboratories) (Professor of Medicine, Director of Laboratories)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Le, NA., Brown, W.V. (2000). Triglyceride-Rich Lipoproteins. In: Wilson, P.W.F. (eds) Atlas of Atherosclerosis. Current Medicine Group, London. https://doi.org/10.1007/978-1-4757-9310-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9310-9_5

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-4757-9312-3

  • Online ISBN: 978-1-4757-9310-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation